The Outcome of GPO-VIR Using at Bamrasnaradura Institute
The objective of this study was to determine the efficacy and safety of GPO-VIR (fixed-dose combinations of d4T/3TC/NVP) in HIV/AIDS patients at Bamrasnaradura Institute. The data of HIV patients who initiated on GPO-VIR during May and June 2002 were retrospective reviewed. Sex, age, prior ART, CD4 counts, Viral Load, Adverse Drug Reaction and Opportunistic Infection were determined. There were 146 patients of which 115 were ART naive and 31 were ART experienced. Mean CD4 increase of naive and experienced groups at week 24 were 121.42 (n =109) and 108.39 (n =28) cells/mm3, respectively (p = 0.477), at week 48: 173.74(n =57) and 204.50(n =14) cells/mm3 respectively (p = 0.537). Mean CD4 increase with baseline CD4 of 0-100, 101-200 and >200 cells/mm3 at week 24 were 123.46 (n =100), 102.62 (n =26) and 114.18(n =11) cells/mm3 respectively (p = 0.540), at week 48: 169.46(n =52), 203.42(n =12) and 216.14(n =7) cells/mm3 respectively (p = 0.463). HIV RNA<50 copies/ml at week 24 in naive and experienced groups were 55/56 (98.2%) and 17/20(85%) respectively (p = 0.054), at week 48: 35/36(97.2%) and 7/7(100%) respectively (p = 1.000). HIV RNA<50 copies/ml with baseline CD4 of 0-100, 101-200 and >200 cells/mm3 at week 24 were 49/50 (98.0%), 16/19 (84.2%) and 7/7 (100.0%) respectively (p = 0.086), at week 48: 29/30 (96.7%), 8/8 (100.0%) and 5/5 (100.0%) respectively (p = 1.000). No significant differences of mean CD4 increase and virological responses were detected among any groups. ADR were found 12/146 (8.22%), 9/146 (6.16%) discontinued or changed regimens. Rash, peripheral neuropathy and lactic acidosis was found 2/146 (1.37%), 4/146 (2.74%) and 3/146 (2.05%) respectively. Hepatitis, lipodystrophy and both peripheral neuropathy and lactic acidosis were found each 1/146(0.68%). In conclusions, GPO-VIR was effective in the treatment of HIV patients. ADR were less than expected. The efficacy, safety and low cost made GPO-VIR suitable and effective to prolong disease- free survival.
2. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings, guidelines for a public health approach. June 2002.
3. World Health Organization. Scaling up antiretroviral therapy in resource-limited settings, guidelines for a public health approach. Oct 2003.
4. Bussiness Line (International edition) Financial Daily from THE HINDU group of publications. Tuesday, August 07, 2001. (Cited 21 November 2006) Available from htpp://www.hinduonnet.com/businessline/2001/08/07/stories/020751 zb.htm
5. B.L.H. Trading Co., LTD. Price List 2003.
6. The Government Pharmaceutical Organization. Price List 2003.
7. กระทรวงสาธารณสุข. แนวทางการดูแลรักษาผู้ติดเชื้อ เอชไอวีและผู้ป่วยโรคเอดส์ เด็กและผู้ใหญ่ในประเทศไทยปี พ.ศ. 2545. กรุงเทพฯ: โรงพิมพ์การศาสนา
8. วรางคณา มั่นสกุล, เพชร รอดอารย์, นที มั่นสกุล. ประสิทธิภาพแลผลข้างเคียงของยาสูตรผสมของ Nevirapine, Stavudine และ Lamivudine ในเม็ดเดียวกัน (GPO-VIR) ในการรักษาผู้ป่วยติดเชื้อเอชไอวี. วชิรเวชสาร 2546; 47: 29-36
9. J.L.Yozviak, R.E. Doerfler, W.C. Woodward. Effectiveness and Tolerability of Nevirapine (NVP), stavudine (d4T) and Lamivudine (3TC). Antiretroviral Therapy (ART) in Clinical Practice, Toronto, Sep. 17-20, 2000. (Presentation 1519)
10. French M, Amin J, Roth N, Carr A, Law M, Emery S, Drumm Cooper D. Randomized, opened-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues
and Nevirapine for previously untreated HIV-1 Infection OzCombo 2 study. HIV Clin Trials. 2000; 3(3): 177-85
Copyright (c) 2009 Disease Control Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the Disease Control Journal considered as academic work, research or analysis of personal opinion of the authors, not opinion of the Department of Disease Control or editorial team. The authors must be responsible for their articles.